Navigation Links
PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
Date:4/10/2013

NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158411/PharmaPoint-Osteoporosis---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, t
'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. PharmaPoint: Osteoporosis - India Drug Forecast and Market Analysis to 2022
2. For Osteoporosis and Osteopenia, Clinical Data and Thought Leaders Opinions Indicate that AMG-785/CDP-7851 and Odanacatib Have Advantages Over Alendronate
3. Active Lifes BioDent Reference Point Indenter Validated in Study Published by Osteoporosis Medical Opinion Leaders
4. Unigenes Phase 2 Study of Oral PTH for the Treatment of Osteoporosis in Postmenopausal Women Featured in Bone
5. Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
6. Research and Markets Announces the Release of Cellulose Ethers Market By Derivative & Application - Global Trends & Forecasts to 2017
7. Research and Markets Announces The Release of Neuromodulation Market - Forecasts to 2017
8. Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts
9. Latin American Electronic Medical Record Market: Key Trends and Forecasts until 2017
10. Oral Transmucosal Drug Delivery. Products, Players, Markets & Forecasts
11. China Human Immunoglobulin Market & 2013 Beverage Forecasts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014   LabStyle Innovations Corp ... Management Solution, today announced that it has closed ... shares of preferred stock and warrants.  No placement ... offering expenses, LabStyle expects to secure net proceeds ... LabStyle intends to use the net ...
(Date:9/23/2014)... , September 23, 2014 ... améliorée lors d,une série de démonstrations personnelles   ... dans le domaine de l,analyse de la ... au stand n° 1035 lors de la réunion ... San Diego , en Californie. FDNA ...
(Date:9/23/2014)... , Sept. 23, 2014 Report Details ... showing you trends, R&D and predicted revenues Do ... inhibitors? Now get the latest analysis for those ... results, opportunities and revenue forecasts. Visiongain,s new ... protein kinase inhibition and related technology. There avoid ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5
... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
(Date:9/23/2014)... PATHWAYS TO PREVENTION WORKSHOP: ROLE OF OPIOIDS IN THE ... The National Institutes of Health is convening a Pathways ... on the long-term effectiveness and potential risks of opioids ... nation,s top experts in the field of pain control ... key NIH scientists who focus on pain related research. ...
(Date:9/23/2014)... From first-hand experience, Matthew O'Farrell knows all about ... can be treated. , A medically retired Army veteran, ... platoon sustained multiple attacks resulting in five casualties. After ... PTSD and honorably discharged from the Army. , “I ... myself from my friends and family,” recalled O’Farrell, who ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Dr. Connie Casad ... medical practices to new office space at 12200 Park Central ... at the office will be Park Cities Aesthetics, Optimal Health ... , In announcing her move, Dr. Casad said, “The patients’ ... treatment they select, we want them to always feel like ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Avid collector Andrew ... 1967 The Doors Eagle Auditorium Seattle concert posters. The Doors ... “Break On Through” that year. The Seattle Eagles Auditorium concert ... “The Doors would return to Eagles Auditorium in November the ... is not known and comes in three colors. The poster ...
Breaking Medicine News(10 mins):Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 2Health News:NIH Pathways to Prevention Workshop: The Role of Opioids in the Treatment of Chronic Pain 3Health News:Virtual Reality software to help treat PTSD 2Health News:Virtual Reality software to help treat PTSD 3Health News:Dr. Connie Casad Moving to New Office Location 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2
... ... New York personal injury attorney, David Perecman. , ... New York, NY (PRWEB) July 14, 2009 -- Three workers, including a ... accident at a privately operated waste transfer plant in Jamaica, Queens. All three apparently ...
... , , ... Masimo (Nasdaq: MASI ), the inventor of Pulse ... 2009 Silver Medical Design Excellence Award in the general hospital devices ... award recognizes Rad-87,s excellence in medical technology engineering and design as ...
... Five hospital board members honored at annual conference ... Minn., July 14 Five Minnesota hospital ... member certification program. , , The ... issues, to hone their leadership skills and to develop governance best ...
... , , , , ... Inc. announced today that the Dakim(R) BrainFitness(TM) System has now been adopted ... their defenses against dementia and memory loss. Dakim has added 136 new ... brain training system provider in the senior care market. , ...
... Calif., July 14, 2009 A drug similar to one ... psoriasis has been found to rescue memory in mice exhibiting ... hope that a new treatment may be on the horizon ... cause of elderly dementia afflicting more than 5 million people ...
... , , ATLANTA , ... of EyeSite(TM) self-service vision testing kiosks, announced today it will team ... educational experience featured in the kiosks. The EyeSite kiosks contribute ... vision assessments and driving consumers to local eye care professionals for ...
Cached Medicine News:Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 2Health News:Personal Injury Attorneys Contemplate Toxic Evidence in the Death of 3 Men in New York 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 2Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 3Health News:Masimo Rad-87(R) Pulse CO-Oximeter(TM) Garners Silver 2009 Medical Design Excellence Award 4Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 2Health News:Dakim BrainFitness Now Used in 286 Senior Living Communities, Adding 136 Sites in 12 Months for Dementia-Fighting System 3Health News:Drug rescues memory lost to Alzheimer's disease 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 2Health News:Eyemaginations Partners with SoloHealth to Enhance Public Eye Health Education with EyeSite(TM) Vision Kiosks 3
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: